De novo design of thioredoxin reductase-targeted heterometallic titanocene –gold compounds of chlorambucil for mechanistic insights into renal cancer

Chem. Commun., 2020, Advance Article DOI: 10.1039/C9CC07406F, CommunicationLeila Tabrizi, Lukman O. Olasunkanmi, Olatomide A. Fadare A chlorambucil-alkynyl mononuclear gold(I) complex and heteronuclear titanocene –gold(I) complex were studied for mechanism of action in renal cancer by experimental and computational methods. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research

Related Links:

Conclusion: Advanced RCC has high morbidity and mortality with an increasing prevalence. Following tyrosine kinase inhibitors, checkpoint inhibitors have a great influence on treatment of advanced RCC, especially the combination of these two strategies. In 2019 these combined strategies demonstrated 5% complete remission with up to 60% objective response rate. While not immediately, but perhaps in the near future, advanced RCC will become a manageable chronic disease, even if a cure is not possible. PMID: 31942809 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
es Claude Cochet Odile Filhol Clear cell renal cell carcinoma (ccRCC) is the third type of urologic cancer. At time of diagnosis, 30% of cases are metastatic with no effect of chemotherapy or radiotherapy. Current targeted therapies lead to a high rate of relapse and resistance after a short-term response. Thus, a major hurdle in the development and use of new treatments for ccRCC is the lack of good pre-clinical models that can accurately predict the efficacy of new drugs and allow the stratification of patients into the correct treatment regime. Here, we describe different 3D cultures models of ccRCC, emphasizing...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
The anti-angiogenic treatment of advanced renal cell carcinoma (RCC) has evolved in the past 15 years owing to the introduction of several vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in clinical practice [1]. VEGFR-TKIs are commonly defined as first- or second-line drugs based on their clinical use [2]; however, a pharmacological classification should refer mainly to their pharmacodynamic and pharmacokinetic properties.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research
The objective of the present study was to investigate the ability of caspase recruitment domain 10 (CARD10) to regulate the NF‑κB signaling pathway and promote the progression of renal cell carcinoma (RCC). Expression of CARD10 in ACHN, 786‑O and HK‑2 cells was evaluated via western blot analysis, as was the epidermal growth factor (EGF)‑induced activation of NF‑κB signaling pathway‑related proteins in cells. The expression of CARD10 was inhibited by CARD10 short hairpin RNA transfection. Cell cycle analysis and MTT assays were used to evaluate cell proliferation. Cell apoptosis was analyzed via flo...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
(UT Southwestern Medical Center) Qing Zhang, Ph.D., and his colleagues identified a possible way to treat tumors while sparing nearby healthy tissue.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
e Rha Cho Ham The molecular characteristics of early-stage clear cell renal cell carcinomas (ccRCCs) measuring ≤7 cm associated with poor clinical outcomes remain poorly understood. Here, we sought to validate genes associated with ccRCC progression and identify candidate genes to predict ccRCC aggressiveness. From among 1069 nephrectomies performed on patients, RNA sequencing was performed for 12 ccRCC patients with aggressive characteristics and matched pairs of 12 ccRCC patients without aggressive characteristics. Using a prospective cohort (ClinicalTrials.gov Identifier: NCT03694912), the expression...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSIONS: We profiled a prognostic signature and established an immune risk score model for ccRCC, which could provide novel predictive markers for patients with ccRCC and an indicator for immunotherapy response measurement. PMID: 31929144 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
(University of Texas M. D. Anderson Cancer Center) Multiple studies out in Nature indicate that a patient's response to immune checkpoint blockade may depend on B cells located in special structures within the tumor.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
CONCLUSIONS: Deep learning can non-invasive distinguish benign renal tumors from RCC using conventional MR imaging in a multi-institutional dataset with good accuracy, sensitivity and specificity comparable to experts and radiomics. PMID: 31937619 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Chemistry | Kidney Cancer